Giuliana Corica, Marco Ceraudo, Claudia Campana, Federica Nista, Francesco Cocchiara, Mara Boschetti, Gianluigi Zona, Diego Criminelli, Diego Ferone, Federico Gatto
Acromegaly is a rare and severe disease caused by an increased and autonomous secretion of growth hormone (GH), thus resulting in high circulating levels of insulin-like growth factor 1 (IGF-1). Comorbidities and mortality rate are closely related to the disease duration. However, in most cases achieving biochemical control means reducing or even normalizing mortality and restoring normal life expectancy. Current treatment for acromegaly includes neurosurgery, radiotherapy and medical therapy. Transsphenoidal surgery often represents the recommended first-line treatment...
2020: Therapeutics and Clinical Risk Management
Quentin Gilliaux, Claude Bertrand, François Hanon, Julian E Donckier
Surgery is the ideal treatment of insulinoma. However, systemic therapy may be required to prevent severe preoperative hypoglycaemia, when surgery is contraindicated, delayed or refused and in case of unresectable metastatic disease. Diazoxide is commonly used but is not always effective and can cause serious side effects. Somatostatin analogues (octreotide and lanreotide) may be an alternative option. We report the case of a 27-year-old patient with insulinoma in whom diazoxide was compared with lanreotide before operation...
May 18, 2020: Acta Chirurgica Belgica
Zhenmei An, Ting Lei, Lian Duan, Pei Hu, Zhongping Gou, Lihui Zhang, Lucie Durand-Gasselin, Nan Wang, Yan Wang, Feng Gu
BACKGROUND: Lanreotide autogel is a somatostatin analog (SSA) approved for the treatment of acromegaly in 73 countries worldwide; however, it is not yet approved in China. The aim of this study was to evaluate the efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release (PR) in Chinese patients with active acromegaly. METHODS: LANTERN was a phase 3, randomized, open-label, non-inferiority study. Patients with active acromegaly who had undergone surgery ≥3 months prior, or were unlikely or unable to undergo surgery, were treated with lanreotide autogel 60/90/120 mg (monthly deep subcutaneous injection) or lanreotide 40 mg PR (intramuscular injection every 7, 10, or 14 days) for 32 weeks...
May 4, 2020: BMC Endocrine Disorders
Akemi Tokutsu, Yosuke Okada, Keiichi Torimoto, Takashi Otsuka, Manabu Narisawa, Akira Kurozumi, Yoshiya Tanaka
Case 1 was a 51-year-old man diagnosed with thyrotropin (TSH)-secreting pituitary tumor. The octreotide loading test showed suppression of TSH secretion. Treatment with lanreotide preoperatively at 90 mg/month resulted in normalization of thyroid function. Three months after treatment initiation, tumor shrinkage was observed, and pituitary tumor resection was performed through transsphenoidal surgery. Case 2 was a 47-year-old woman in whom the octreotide loading test showed suppressed TSH secretion. Treatment with lanreotide preoperatively at 90 mg/month resulted in normalization of thyroid function...
April 27, 2020: Neuro Endocrinology Letters
Leticia P Leonart, Bruno S Riveros, Murray D Krahn, Roberto Pontarolo
OBJECTIVES: To conduct a cost-utility analysis comparing drug strategies involving octreotide, lanreotide, pasireotide, and pegvisomant for the treatment of patients with acromegaly who have failed surgery, from a Brazilian public payer perspective. METHODS: A probabilistic cohort Markov model was developed. One-year cycles were employed. The patients started at 45 years of age and were followed lifelong. Costs, efficacy, and quality of life parameters were retrieved from the literature...
April 16, 2020: Neuroendocrinology
Annamaria Anita Livia Colao, M D Bronstein, Thierry Brue, Laura De Marinis, Maria Fleseriu, Mirtha Guitelman, Gerald Raverot, Ilan Shimon, Jürgen Fleck, Pritam Gupta, Alberto M Pedroncelli, Monica R Gadelha
OBJECTIVE: In the Phase III PAOLA study ( NCT01137682), enrolled patients had uncontrolled acromegaly despite ≥6 months of octreotide/lanreotide treatment before study start. More patients achieved biochemical control with long-acting pasireotide versus continued treatment with octreotide/lanreotide (active control) at month 6. The current work assessed the extent of comorbidities at baseline and outcomes during a long-term extension. DESIGN/METHODS: Patients receiving pasireotide 40 or 60 mg at core study end could continue on the same dose in an extension phase if biochemically controlled, or receive pasireotide 60 mg if uncontrolled...
March 1, 2020: European Journal of Endocrinology
Roberta Elisa Rossi, Pietro Invernizzi, Vincenzo Mazzaferro, Sara Massironi
BACKGROUND: Type-1 gastric neuroendocrine tumors represent a recurring disease and long-acting somatostatin analogs can inhibit both gastrin release and endocrine cell proliferation. The efficacy and timing of this treatment are still unclear. We performed a systematic review of the literature to clarify the role of somatostatin analog treatment in type-1 gastric neuroendocrine tumors. METHODS: A computerized literature search was performed using relevant keywords to identify all the pertinent articles published in the last 15 years...
March 2020: United European Gastroenterology Journal
Bernardo Marques, Ana Raquel Monteiro, Raquel G Martins, Joana Couto, Fernando Rodrigues, João Ribeiro
No abstract text is available yet for this article.
March 2020: Pancreas
Daphne Adelman, Xuan-Mai Truong Thanh, Marion Feuilly, Aude Houchard, David Cella
INTRODUCTION: Somatostatin analogues are used to treat symptoms and slow tumour progression in patients with neuroendocrine tumours (NETs) and carcinoid syndrome and to reduce hormone secretion and pituitary tumour volume in patients with acromegaly. A new syringe for lanreotide autogel/depot (LAN) was developed following feedback from a human factors study to improve ease of injection compared with previous syringes. PRESTO aimed to assess preferences of nurses between the LAN new syringe and the octreotide long-acting release (LAR) syringe...
March 11, 2020: Advances in Therapy
Hongjuan Zheng, Shishi Zhou, Wanfen Tang, Qinghua Wang, Xia Zhang, Xiayun Jin, Ying Yuan, Jianfei Fu
BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant disorder arising from mutations of the MEN1 tumor suppressor gene on chromosome 11q13; MEN1 is characterized by the development of neuroendocrine tumors, including those of the parathyroid, gastrointestinal endocrine tissue and anterior pituitary. Additionally, thymic neuroendocrine tumors in MEN1 are also rarely reported. CASE PRESENTATION: This case report observed a family that presented with MEN1 p...
March 4, 2020: BMC Neurology
Vikas Prasad, Raj Srirajaskanthan, Christos Toumpanakis, Chiara Maria Grana, Sergio Baldari, Tahir Shah, Angela Lamarca, Frédéric Courbon, Klemens Scheidhauer, Eric Baudin, Xuan-Mai Truong Thanh, Aude Houchard, Clarisse Dromain, Lisa Bodei
PURPOSE: PRELUDE aimed to assess use and effectiveness/safety of lanreotide autogel/depot (LAN) combined with 177 Lu-DOTATOC or 177 Lu-DOTATATE (LAN-peptide receptor radionuclide therapy [PRRT]) in patients with progressive neuroendocrine tumours (NETs). METHODS: International, non-interventional, retrospective, non-comparative analysis of medical records from patients with progressive metastatic or locally advanced grade 1 or 2 gastroenteropancreatic (GEP)- or lung-NETs...
February 15, 2020: European Journal of Nuclear Medicine and Molecular Imaging
Nidan Qiao, Min He, Ming Shen, Qilin Zhang, Zhaoyun Zhang, Xuefei Shou, Yongfei Wang, Yao Zhao, Nicholas A Tritos
Objective: Comprehensive evidence comparing different medications for acromegaly is scarce. The aim of this study was to perform a network meta-analysis based on evidence from both randomized trials and observational studies of medical treatments for acromegaly. Methods: Electronic databases were searched for both observational studies and randomized trials that enrolled acromegaly patients treated with medications of interest. Simulated trials were generated by a machine learning algorithm and then synthesized with Bayesian random-effects network meta-analyses...
April 2020: Endocrine Practice
A Croitoru, I Dinu, V Herlea, G Becheanu, M Grasu, I Lupescu, S O Dima, F Buica, T Dumitrascu, C Lungulescu, V M Croitoru, A Tanase, S M Negru, I M Gramaticu
We report the case of a 55-year-old-male with a large cell metastatic pancreatic neuroendocrine carcinoma treated for 14 months with lanreotide autogel having a stable disease (SD) and not responding to chemotherapy. The somatostatin analogues (SSA) were introduced after an episode of diarrhea and controlled the disease. Progression-free survival (PFS) as determined by Computerized Tomography (CT) scans was obtained for 14 months. After more than a year, the patient's health state deteriorated along with progressive disease...
July 2019: Acta endocrinologica: the international journal of the Romanian Society of Endocrinology
Tal Grenader, Marianne E Pavel, Philippe B Ruszniewski, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Xuan-Mai Truong Thanh, Martyn E Caplin
Accessible prognostic tools are needed to individualize treatment of neuroendocrine tumors (NETs). Data suggest neutrophil/lymphocyte ratios (NLRs) have prognostic value in some solid tumors, including NETs. In the randomized double-blind CLARINET study (NCT00353496; EudraCT 2005-004904-35), the somatostatin analog lanreotide autogel/depot increased progression-free survival (PFS) compared with placebo in patients with inoperable or metastatic intestinal and pancreatic NETs (grades 1-2, Ki-67 < 10%)...
January 21, 2020: Anti-cancer Drugs
Zaina Adnan, Ilan Shimon
Objective: Acromegaly is a rare disease. Medical management with somatostatin analogs and the growth hormone receptor antagonist pegvisomant can normalize insulin-like growth factor-1 (IGF1) levels after failed surgery and decrease mortality and comorbidities. We present a case report of a patient with acromegaly on chronic hemodialysis resistant to first-generation, long-acting somatostatin analogs with remarkable response to pasireotide long-acting release (PAS-LAR). Methods: A 66-year-old woman with acromegaly and chronic renal failure on hemodialysis resistant to lanreo-tide autogel (at 120 mg) was treated successfully with PAS-LAR...
March 2019: AACE Clinical Case Reports
Daphne T Adelman, Dirk Van Genechten, Clémentine M Megret, Xuan-Mai T Truong Thanh, Philippa Hand, Wendy A Martin
In the Original Article, there is an error in the "participants" section of Results. The correct sentence is "A total of 213 participants took part in the studies, including 34 patients with acromegaly and 28 patients with NETs".
February 2020: Advances in Therapy
Stephan Petersenn, Aude Houchard, Caroline Sert, Philippe J Caron
PURPOSE: PRIMARYS (NCT00690898) was a 48-week, open-label, phase 3b study, evaluating treatment with the somatostatin receptor ligand lanreotide autogel (stable dose: 120 mg/28 days) in treatment-naïve patients with growth hormone (GH)-secreting pituitary macroadenoma. This post hoc analysis aimed to evaluate factors predictive of long-term responses. METHODS: Potential predictive factors evaluated were: sex, age, and body mass index at baseline; and GH, insulin-like growth factor-1 (IGF-1), and tumor volume (TV) at baseline and week 12, using univariate regression analyses...
April 2020: Pituitary
Koenraad Blot, Luc Duchateau, Benedicte Lescrauwaet, Nilani Liyanage, David Ray, Beloo Mirakhur, Aaron I Vinik
Purpose: The purpose of this analysis of patient-reported outcomes from the ELECT (Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment) trial (NCT00774930) was to explore the effect of lanreotide on symptoms of carcinoid syndrome. Specifically, this post hoc analysis was designed to identify the most important patient-reported outcomes for patients in ELECT. Methods: The post hoc analysis of ELECT, a placebo-controlled study of lanreotide in patients with neuroendocrine tumors, evaluated patient-reported outcomes during the double-blind phase of the trial, specifically daily diarrhea and flushing symptoms, octreotide rescue use, and the EORTC QLQ-C30 and QLQ-GINET21 questionnaires at baseline and week 12...
2019: Patient related Outcome Measures
Sofia Castro Oliveira, João Sérgio Neves, Pedro Souteiro, Sandra Belo, Ana Isabel Oliveira, Helena Moreira, Paulo Mergulhão Gomes, Lígia Coelho, Cristina Sarmento, Elsa Fonseca, Celestino Neves, Paula Freitas, Davide Carvalho
Introduction: Adrenocorticotropic hormone (ACTH) ectopic production is a rare cause of Cushing syndrome (CS). The most commonly associated tumours are small-cell lung carcinoma along with bronchial and thymic carcinoids. To date, only 5 cases have been published in the literature featuring ectopic ACTH secretion from metastatic acinic cell carcinoma (ACC) of the parotid gland. We hereby describe a very uncommon case of ectopic CS (ECS) unveiling a metastatic parotid ACC. Case Presentation: A 46-year-old man with hypertension and dyslipidemia diagnosed 4-months before, as well as new-onset diabetes mellitus unveiled 1-month earlier, was referred to emergency department for hypokalemia...
2019: Case Reports in Endocrinology
Torbjörn Ström, Gordana Kozlovacki, Peter Myrenfors, Martin Almquist
Purpose: Evaluate patients' and nurses' experiences, including injection problem frequency, with the somatostatin analogues (SSAs) lanreotide autogel® (Somatuline® autogel® , deep subcutaneous) and octreotide long-acting release (LAR) (Sandostatin® LAR® , intramuscular) when treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: An observational, cross-sectional study across 2 NET centers in Sweden. Questionnaires based on participants' most recent injection experience were sent to patients with GEP-NETs treated with octreotide or lanreotide, and to nurses administering these treatments...
2019: Patient Preference and Adherence
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"